# Zofin to Treat COVID-19 Long Haulers

> **NCT05228899** · PHASE1,PHASE2 · COMPLETED · sponsor: **ZEO ScientifiX, Inc.** · enrollment: 18 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Zofin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05228899
- **Lead sponsor:** ZEO ScientifiX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-14
- **Primary completion:** 2023-10-01
- **Final completion:** 2023-10-18
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228899, "Zofin to Treat COVID-19 Long Haulers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05228899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*